Quotes 5-day view Delayed Nasdaq
10/19/2020
10/20/2020
10/21/2020
10/22/2020
10/23/2020
Date
198.22(c)
198.02(c)
197.71(c)
200.66(c)
196.92(c)
Last
698 890
444 469
402 896
617 372
479 621
Volume
-1.35% -0.10% -0.16% +1.49% -1.86% Change
Sales 2020
1 502 M - -
Net income 2020
-47,9 M - -
Net cash position 2020
1 493 M - -
P/E ratio 2020
-321x
Yield 2020
-
Sales 2021
1 824 M - -
Net income 2021
15,7 M - -
Net cash position 2021
1 548 M - -
P/E ratio 2021
1 634x
Yield 2021
-
Capitalization
34 263 M 34 263 M -
EV / Sales 2020
21,8x
EV / Sales 2021
17,9x
Nbr of Employees
1 605
Free-Float
99,3%
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV...
Notations Surperformance© of Seagen Inc.
Trading Rating : Investor Rating :
All news about SEAGEN INC.
News in other languages on SEAGEN INC.
Wall Street closes broadly higher on deal news, vaccine hopes
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SEAGEN INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
195,59 $
Last Close Price
196,92 $
Spread / Highest target
29,0%
Spread / Average Target
-0,68%
Spread / Lowest Target
-29,9%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
